Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4129 publications

Risk of serious infections in patients with inflammatory bowel disease treated with biologic and small molecule therapies: A nationwide cohort study.

Risk of serious infections in patients with inflammatory bowel disease treated with biologic and small molecule therapies: A nationwide cohort study.

Journal: Journal of Crohn's & colitis
Published: December 15, 2025

A Rare Presentation of Crohn's Disease: A Case Report.

A Rare Presentation of Crohn's Disease: A Case Report.

Journal: Cureus
Published: December 13, 2025

HLA-DQA1*05:01 and DQA1*05:05 inform choice of anti-tumor necrosis factor and concomitant use of immunomodulators in patients with inflammatory bowel disease.

HLA-DQA1*05:01 and DQA1*05:05 inform choice of anti-tumor necrosis factor and concomitant use of immunomodulators in patients with inflammatory bowel disease.

Journal: Journal of Crohn's & colitis
Published: December 13, 2025

High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study.

High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study.

Journal: Scandinavian journal of gastroenterology
Published: December 08, 2025

Efficacy and safety of IL-23p19 and IL-12/23p40 inhibitors in moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.

Efficacy and safety of IL-23p19 and IL-12/23p40 inhibitors in moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.

Journal: Annals of medicine
Published: December 03, 2025

An evaluation of guselkumab for the treatment of ulcerative colitis.

An evaluation of guselkumab for the treatment of ulcerative colitis.

Journal: Expert opinion on biological therapy
Published: December 01, 2025

Systematic Review and Network Meta-Analysis: Evaluating the Impact of advanced therapies for Moderate-to-Severe Ulcerative Colitis on Health-Related Quality of Life.

Systematic Review and Network Meta-Analysis: Evaluating the Impact of advanced therapies for Moderate-to-Severe Ulcerative Colitis on Health-Related Quality of Life.

Journal: Journal of Crohn's & colitis
Published: November 24, 2025

AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease.

AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease.

Journal: Gastroenterology
Published: November 22, 2025

Serum Protein Profiles Differ with Adalimumab and Ustekinumab Treatment in Moderately to Severely Active Crohn's Disease.

Serum Protein Profiles Differ with Adalimumab and Ustekinumab Treatment in Moderately to Severely Active Crohn's Disease.

Journal: Journal of Crohn's & colitis
Published: November 19, 2025

Pyzchiva (ustekinumab-ttwe): A New Biosimilar for Psoriasis.

Pyzchiva (ustekinumab-ttwe): A New Biosimilar for Psoriasis.

Journal: The Annals of pharmacotherapy
Published: November 14, 2025

Comprehensive assessment of 5 interleukin inhibitors for the treatment of psoriasis: scientific guidance based on drug selection recommendations for Chinese medical institutions.

Comprehensive assessment of 5 interleukin inhibitors for the treatment of psoriasis: scientific guidance based on drug selection recommendations for Chinese medical institutions.

Journal: Journal of pharmaceutical policy and practice
Published: November 10, 2025

Shift from ustekinumab originator to biosimilars in Denmark.

Shift from ustekinumab originator to biosimilars in Denmark.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: November 07, 2025
Showing 1-12 of 4,129

Last Updated: 01/07/2026